Response of metastatic recurrent neuroblastoma to nitisinone: A modulator of tyrosine metabolism

Pediatric Blood and Cancer

Volumn 46, Issue 4, 2006, Pages 517-520

  Kobrinsky, Nathan L ^a,b   Sjolander, Diane E ^a  

^a MeritCare Roger Maris Cancer Center   (United States)

^b UNIVERSITY OF NORTH DAKOTA   (United States)

Author keywords

HVA; Metanephrine; Neuroblastoma; Nitisinone; Tyrosine; VMA

Indexed keywords

CARBOPLATIN; CATECHOLAMINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; HOMOVANILLIC ACID; HYDROXYUREA; IFOSFAMIDE; MESNA; METADRENALIN; METHOTREXATE; NITISINONE; TOPOTECAN; TYROSINE; VANILMANDELIC ACID; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; AMINO ACID METABOLISM; ARTICLE; CANCER PAIN; CASE REPORT; CHILDHOOD CANCER; CONJUNCTIVITIS; DRUG EFFICACY; EYE IRRITATION; GENE AMPLIFICATION; HUMAN; LOW DRUG DOSE; MALE; METASTASIS; NEUROBLASTOMA; ONCOGENE C MYB; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT OUTCOME; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOHEXANONES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FATAL OUTCOME; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; NITROBENZOATES; REMISSION INDUCTION; TREATMENT OUTCOME; TYROSINE;

EID: 33644689426     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20420     Document Type: Article

References (10)

1. Bowman LC, Hancock ML, Santana VM, et al. Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: The St. Jude Children's Research Hospital experience, 1962 to 1998. J Clin Oncol 1991;9:1599-1608.
2. Matthay KK, Villabianca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
3. Shitara T, Shimada A, Tsuchida Y, et al. Successful clinical response to irinotecan in relapsed neuroblastoma. Med Pediatr Oncol 2003;40:126-128.
4. Graham-Pole J, Salmi T, Anton AH, et al. Tumor and urine catecholamines (CATS) in neurogenic tumors. Correlations with other prognostic factors and survival. Cancer 1983;51:834-839.
5. Labrosse EH, Com-Nougou C, Zucker JM, et al. Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors. Cancer Res 1980;40:1995-2001.
6. Lang WE, Siegel SE, Shaw KNF, et al. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 1978;62:77-83.
7. Schulz A, Ort O, Beyer P, et al. SC-0051, a 2-benzoyl-cyclohexane 1,3 dione bleaching herbicine, is a potent inhibitor of the enzyme p-hydroxyphenypyruvate dioxygenase. FEBS Lett 1993;318:162-166.
8. Ellia MK, Whitfield AC, Gowans LA, et al. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)- cyclohexane 1,3 dione and 2 (2 chloro-4-methylsulfonylbenzoyl)-cyclohexane 1,3 dione. Toxicol App Pharmacol 1995;133:12-19.
9. Mitchell GA, Grompe M, Lambert M, et al. Hyertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic & molecular bases of inherited disease, 8th edn. Vol 2. New York: McGraw-Hill; 2001. pp 1777-1805.
10. Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. N Engl J Med. 2002;347:2111-2121.